Oxybutinin

# Oxybutinin ## Overview - **Classification**: Anticholinergic, antispasmodic, muscarinic receptor antagonist. - **Mechanism**: Directly relaxes bladder smooth muscle. Blocks muscarinic acetylcholine receptors, increasing bladder capacity and reducing uninhibited detrusor contractions. ## Primary Indications 1. **Overactive Bladder (OAB)** - Management of symptoms like urge urinary incontinence, urgency, and frequency. 2. **Neurogenic Detrusor Overactivity (NDO)** - Especially in children with spina bifida. ## Adult Dosing ### Standard Dosing **Overactive Bladder (OAB) - Oral Immediate-Release (IR)** - **Dose**: **5 mg** - **Frequency**: 2-3 times daily - **Route**: Oral - **Maximum**: **20 mg/day** **Overactive Bladder (OAB) - Oral Extended-Release (ER)** - **Dose**: Initial **5-10 mg** - **Frequency**: Once daily - **Route**: Oral - **Maximum**: **30 mg/day** **Overactive Bladder (OAB) - Transdermal Patch (Oxytrol®)** - **Dose**: **3.9 mg/day** delivered - **Frequency**: Apply 1 patch twice weekly (every 3-4 days) - **Route**: Transdermal **Overactive Bladder (OAB) - Topical Gel (Gelnique®)** - **Dose**: **100 mg** (10% gel, one pump or packet) - **Frequency**: Once daily - **Route**: Topical ### Dose Adjustments - **Renal Impairment**: Use with caution. No specific adjustment, but monitor for increased side effects. - **Hepatic Impairment**: Use with caution, especially with moderate-severe impairment. Consider lower initial doses. - **Elderly Patients**: Start with lower doses (e.g., IR **2.5 mg** 2-3 times daily; ER **5 mg** once daily) due to increased anticholinergic sensitivity. Monitor for CNS effects. ## Pediatric Dosing *Note: Oxybutynin use in children under 6 years for OAB is generally off-label and requires careful consideration due to limited data and increased anticholinergic sensitivity.* ### Neonates (0-28 days) - **Not Recommended**: Insufficient safety and efficacy data. High risk of anticholinergic side effects. ### Infants (1-12 months) - **Not Recommended**: Insufficient safety and efficacy data. High risk of anticholinergic side effects. ### Children (1-5 years) - For Neurogenic Detrusor Overactivity (NDO) - **Dose**: Initial **0.2 mg/kg/dose** - **Frequency**: 2-4 times daily - **Maximum**: **5 mg/dose** or **15 mg/day** (whichever is less) - **Special Notes**: Use with extreme caution. Titrate slowly. Monitor closely for anticholinergic effects. ### Children (6-12 years) - For Neurogenic Detrusor Overactivity (NDO) - **Dose**: Initial **5 mg** (IR formulation is FDA-approved for this age group) - **Frequency**: 2-3 times daily - **Maximum**: **20 mg/day** - **Special Notes**: ER formulation generally not recommended or used off-label. ### Adolescents (13-18 years) - **Dose**: Generally follow adult dosing recommendations. - **Maximum**: Adult maximum doses apply (e.g., IR **20 mg/day**, ER **30 mg/day**). ## Safety Information ### Contraindications - **Absolute**: Urinary retention, gastric retention, uncontrolled narrow-angle glaucoma. - **Absolute**: Severe decreased GI motility (e.g., paralytic ileus, toxic megacolon). - **Absolute**: Hypersensitivity to oxybutynin or components. ### Common Adverse Effects - **Very Common (>10%)**: Dry mouth (xerostomia), constipation, headache, dizziness, blurred vision, somnolence, nausea. - **Common (1-10%)**: Diarrhea, dyspepsia, urinary tract infection, fatigue, dry eyes, rash. - **Serious but Rare**: Angioedema, heat prostration (due to reduced sweating), severe cognitive impairment/delirium, QT prolongation. ### Key Drug Interactions - **CYP3A4 Inhibitors (e.g., ketoconazole, erythromycin)**: Increase oxybutynin levels. Monitor for increased anticholinergic effects. - **Other Anticholinergics (e.g., tricyclic antidepressants, antihistamines)**: Additive anticholinergic effects (e.g., severe dry mouth, constipation, confusion). Avoid concurrent use or use with extreme caution. - **Cholinesterase Inhibitors (e.g., donepezil)**: May reduce the efficacy of cholinesterase inhibitors. Monitor cognitive function. - **GI Motility Drugs (e.g., prokinetics)**: Oxybutynin may antagonize effects of prokinetic agents. ## Monitoring & Follow-up - **Before Treatment**: Assess for contraindications (e.g., glaucoma, bladder outlet obstruction). Review all current medications. - **During Treatment**: Monitor for anticholinergic side effects (e.g., dry mouth, constipation, urinary retention, blurred vision, cognitive changes). Assess symptom improvement. - **Clinical Signs**: Watch for significantly decreased urination, severe abdominal pain, new or worsening confusion, eye pain, or fever without sweating. ## Clinical Pearls - 💡 **Tip 1**: Start with the lowest effective dose, especially in the elderly, and titrate slowly to minimize anticholinergic side effects. - 💡 **Tip 2**: Counsel patients on strategies to manage dry mouth (sugar-free candy/gum, sips of water) and constipation (increased fluid/fiber intake, stool softeners). - 💡 **Tip 3**: Transdermal patch and topical gel formulations may have a lower incidence of dry mouth due to bypassing first-pass metabolism. - 💡 **Tip 4**: Warn patients about the risk of heat prostration due to reduced sweating, especially in hot environments or during physical activity. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.